Nutra Pharma (Nutra Pharma) Debt-to-Equity : -0.52 (As of Sep. 2022)

View and export this data going back to . Start your Free Trial

What is Nutra Pharma Debt-to-Equity?

Nutra Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $7.88 Mil. Nutra Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $0.15 Mil. Nutra Pharma's Total Stockholders Equity for the quarter that ended in Sep. 2022 was $-15.61 Mil. Nutra Pharma's debt to equity for the quarter that ended in Sep. 2022 was -0.51.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Nutra Pharma's Debt-to-Equity or its related term are showing as below:

NPHC's Debt-to-Equity is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.3
* Ranked among companies with meaningful Debt-to-Equity only.

Nutra Pharma Debt-to-Equity Historical Data

The historical data trend for Nutra Pharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nutra Pharma Debt-to-Equity Chart

Nutra Pharma Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Debt-to-Equity

Get a 7-Day Free Trial

-0.64

-0.57

-0.72

-0.44

-0.39

Nutra Pharma Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Debt-to-Equity	Get a 7-Day Free Trial															-0.36	-0.39	-0.47	-0.53	-0.52

Competitive Comparison of Nutra Pharma's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Nutra Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nutra Pharma's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nutra Pharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Nutra Pharma's Debt-to-Equity falls into.

Nutra Pharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Nutra Pharma's Debt to Equity Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(7.678	+	0.517)	/	-20.878
	=	-0.39

Nutra Pharma's Debt to Equity Ratio for the quarter that ended in Sep. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(7.883	+	0.152)	/	-15.61
	=	-0.51

Nutra Pharma (OTCPK:NPHC) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Nutra Pharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Nutra Pharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Nutra Pharma (Nutra Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nutra Pharma Corp (OTCPK:NPHC) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

1537 NW 65th Avenue, Plantation, FL, USA, 33313

Website

https://www.nutrapharma.com

Nutra Pharma Corp operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. It also develops proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), and pain in humans. Some of its drug names are Cobroxin, Nyloxin, RPI-78M, RPI-MN and Pet Pain-Away.

Executives

Rik J Deitsch	officer: Chief Executive Officer	4001 NW 73 WAY, CORAL SPRINGS FL 33065
Dan Oran	director	8411 W OAKLAND PARK BLVD, #201, SUNRISE FL 33351
Bruno Sartori	other: Former CFO	275 COMMERCIAL BLVD, STE 260, FT LAUDERDALE FL 33308
Harold Henry Rumph	director, officer: President - ReceptoPharm	1537 N.W. 65TH AVENUE, PLANTATION FL 33313
David Michael Isserman	officer: Chief Marketing Officer	2776 UNIVERSITY DRIVE, CORAL SPRINGS FL 33065
Garry Pottruck	director	10768 NW 18TH CT, CORAL SPRINGS FL 33071
Paul F Reid	director	9610 NW 24 CT, SUNRISE FL 33322
Michael Doherty	director, officer: Executive Chairman
Tanvir A Khandaker	director	387 PARK AVENUE SOUTH THIRD FLOOR, NEW YORK NY 10016
Stewart Alan Lonky	director	1158 CHAUTAUQUA BLVD., PACIFIC PALISADES CA 90272
Stanley Jack Cherelstein	director	2401 SW MANOR HILL DRIVE, PALM CITY FL 34990
Michael Flax	director, officer: Chief Financial Officer	2499 BANYAN RD, BOCA RATON FL 33432
Mcclelland David C Sr	director	P.O. BOX 263, FINDLEY LAKE NY 14736
Mitchell S Felder	director	PO BOX 1332, HERMITAGE PA 16148
Khalsa Soram Singh Md	director	436 N BEDFORD DR, BEVERLY HILLS CA 90210

Nutra Pharma (Nutra Pharma) Headlines

From GuruFocus

Nutra Pharma Partners with NxGen Brands for Nyloxin® Distribution

By Marketwired Marketwired • 04-19-2018